Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis

Juliette Brenner1, Cinthia J Ruhe1, Ilse Kulderij1

  • 1From the Department of Neurology (J.B., C.J.R., I.K., A.E.M.B., Y.S.C., C.N.K., J.C.P.V., A.A.G.T., B.T., L.P.K., M.A.A.M.d.B., M.R.M., J.K., R.W.v.S., J.M.d.V., R.F.N., P.A.E.S.S., M.J.T.), Erasmus University Medical Center, Rotterdam; Department of Neurology (S.H.C.O.), Amsterdam University Medical Center; Department of Immunology (S.V.), Erasmus University Medical Center, Rotterdam; Laboratory of Medical Microbiology and Immunology Microvida (M.W.J.S.), Tilburg; and Department of Neurology & Alzheimer Center (E.v.d.B.), Erasmus University Medical Center, Rotterdam, the Netherlands.

Neurology
|November 20, 2024
PubMed
Summary

Recovery from anti-NMDA receptor (anti-NMDAR) encephalitis can take up to 3 years, with many patients experiencing lasting cognitive and psychosocial issues. The modified Rankin Scale (mRS) may not fully reflect these long-term challenges in patients with anti-NMDAR encephalitis.